A previous study found that GLP‐1 receptor agonists and other incretin‐based therapies for T2DM patients were associated with a low risk of developing AS, and their vasculoprotective effects were related to vasodilation, the prevention, and development of endothelial dysfunction, lipid homeostasis, and antiproliferative and anti‐inflammatory effects.65 The gene discussed is GCG; the disease is type 2 diabetes mellitus.